Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.

Since it went on the market, the newer device has been the subject of several reports of hemolysis. This would seem ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

A federal judge has paused the merger of the only two companies developing a heart device made for high-risk patients suffering from ...

Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.

Recently published research shows a medical device may be beneficial for patients who have previously had a stroke and are planning to undergo a transcatheter aortic valve replacement, a type of heart ...

SILVER SPRING, MD — Unanimously disappointed with the end point used to determine clinical benefit, advisors to the US Food and Drug Administration (FDA) agreed the Sentinel Cerebral Protection System ...

REHOVOT, Israel--(BUSINESS WIRE)--Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it ...

The ACURATE study of the Accurate neo2 TAVR device by Boston Scientific Corp., failed to demonstrate the device is non-inferior to established devices, but the COVID-19 pandemic threw up some ...